# Study of HS-10517 in Chinese Adult Participants

> **NCT05779579** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 340 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** HS-10517 Dose 1
- **DRUG:** HS-10517 Dose 2
- **DRUG:** HS-10517 Dose 3
- **DRUG:** HS-10517 Dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05779579
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05779579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05779579, "Study of HS-10517 in Chinese Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05779579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*